Chimeric antigen receptors for t-cell based therapy

Eleanor Cheadle, Eleanor J. Cheadle, Vicky Sheard, Andreas A. Hombach, Markus Chmielewski, Tobias Riet, Cor Berrevoets, Erik Schooten, Cor Lamers, Hinrich Abken, Reno Debets, David E. Gilham

    Research output: Contribution to journalArticlepeer-review


    The Chimeric Antigen Receptor (CAR) consists of an antibody-derived targeting domain fused with T-cell signaling domains that, when expressed by a T-cell, endows the T-cell with antigen specificity determined by the targeting domain of the CAR. CARs can potentially redirect the effector functions of a T-cell towards any protein and nonprotein target expressed on the cell surface as long as an antibody or similar targeting domain is available. This strategy thereby avoids the requirement of antigen processing and presentation by the target cell and is applicable to nonclassical T-cell targets like carbohydrates. This circumvention of HLA-restriction means that the CAR T-cell approach can be used as a generic tool broadening the potential of applicability of adoptive T-cell therapy. Proof-of-principle studies focusing upon the investigation of the potency of CAR T-cells have primarily focused upon the genetic modification of human and mouse T-cells for therapy. This chapter focuses upon methods to modify T-cells from both species to generate CAR T-cells for functional testing. © 2012 Springer Science+Business Media, LLC.
    Original languageEnglish
    Pages (from-to)645-666
    Number of pages21
    JournalMethods in Molecular Biology
    Publication statusPublished - 2012


    • Chimeric antigen receptor
    • Lentivirus
    • Retrovirus
    • RNA
    • T-cell
    • Transduction
    • Transfection


    Dive into the research topics of 'Chimeric antigen receptors for t-cell based therapy'. Together they form a unique fingerprint.

    Cite this